^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    galectin 3 inhibitors

    Associations

    News

    Trials
    Company:
    Galectin Therap
    Drug class:
    Galectin-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    SERUM GALECTIN-3 IN PORTAL HYPERTENSION DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH) (AASLD 2023)
    Serum galectin-3 might not be a useful biomarker of disease activity in NASH, particularly in compensated cirrhosis with portal hypertension. As in the oncology setting, intra-tissular galectin-3 might be a more relevant biomarker of disease activity and a predictor of response to galectin-3 inhibitor treatment2. 1 Goodman, et al.
    PD(L)-1 Biomarker • IO biomarker
    |
    LGALS3 (Galectin 3)
    |
    galectin 3 inhibitors
    almost5years
    Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. (PubMed, J Immunother Cancer)
    Belapectin+pembrolizumab therapy has activity in MM and HNSCC. Increased Gal-3 expression, expansion of effector memory T cells, and decreased M-MDSCs correlated with clinical response. Further investigation is planned.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • belapectin (GR-MD-02) • galectin 3 inhibitors